- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05382858
PSA Versus STN DBS for TD-PD (PSA-STN)
February 12, 2023 updated by: LI DIANYOU, Ruijin Hospital
Deep Brain Stimulation of the Posterior Subthalamic Area (PSA) Versus Subthalamic Nucleus (STN) for Tremor-dominant Parkinson's Disease: a Prospective, Randomized, Double-blinded, Cross-over Trial
The aim of this study is to compare the effectiveness of the deep brain stimulation in the posterior subthalamic area (PSA) versus the subthalamic nucleus (STN) for the treatment of tremor-dominant Parkinson's disease (PD) in a randomized, double-blinded, cross-over manner.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, double-blinded, crossover trial aiming at comparing the efficacy of PSA and STN DBS in treating tremor-dominant PD.
Enrolled patients will undergo bilateral DBS surgery, targeting both PSA and STN with single trajectory.
Two months post-implantation, patients enter a 4-month double-blinded crossover phase with PSA and STN DBS in randomized order.
After 6 months post-implantation (at the end of the crossover phase), patients enter an open-label phase during which programming parameters are not restricted until the termination of the study at 12-month follow-up.
Study Type
Interventional
Enrollment (Anticipated)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Recruiting
- Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine
-
Contact:
- Dianyou Li, MD,PhD
- Email: ldy11483@rjh.com.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- diagnosis of idiopathic Parkinson's disease
- tremor-dominant subtype in the on-medication condition
- modified Hoehn-Yahr scale of 2 to 4 in the on-medication condition
- receiving regular anti-parkinsonian drugs for more than 6 weeks
- good compliance and written informed consent provided
Exclusion Criteria:
- Atypical parkinsonism
- History of stroke, encephalitis, neuroleptic uses, MRI scan with evidence of significant brain atrophy, lacunar infracts, or other conditions that might interfere with the intracranial surgery
- Presence of cognitive, or psychiatric or other co-morbidities (e.g., dementia, epilepsy, cranial traumatism, brain tumor, schizophrenia, severe depression or bipolar disorder, personality disorder, etc.) that might interfere with the patient's ability to complete the evaluations or to provide informed consent
- Presence of anatomical abnormalities in the target region
- Clinically significant medical history that would increase pre-/post-operative complications
- Other conditions considered by the investigators that might interfere with the surgery procedure, the follow-ups, and the interpretation of the data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PSA-STN
Participants randomized in this arm will receive bilateral PSA stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral STN stimulation for another two months.
|
active DBS with optimal stimulating parameters
|
EXPERIMENTAL: STN-PSA
Participants randomized in this arm will receive bilateral STN stimulation in the first two months in the randomized phase and then will be crossovered to the bilateral PSA stimulation for another two months.
|
active DBS with optimal stimulating parameters
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 4 months
Time Frame: 4 months
|
in the off-medication condition
|
4 months
|
Change from baseline Movement Disorder Society-sponsord Unified Parkinson's Disease Rating Scale Part III at 6 months
Time Frame: 6 months
|
in the off-medication condition
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events
Time Frame: up to 12 months after surgery
|
up to 12 months after surgery
|
|
Change from baseline Fahn-Tolosa-Marin Clinical Rating Scale for Tremor to 4 months
Time Frame: 4 months
|
4 months
|
|
Change from baseline Fahn-Tolosa-Marin Clinical Rating Scale for Tremor to 6 months
Time Frame: 6 months
|
6 months
|
|
Change from baseline Timed up and go test to 4 months
Time Frame: 4 months
|
in the off-medication condition
|
4 months
|
Change from baseline Timed up and go test to 6 months
Time Frame: 6 months
|
in the off-medication condition
|
6 months
|
Change from baseline Berg balance scale to 4 months
Time Frame: 4 months
|
in the off-medication condition
|
4 months
|
Change from baseline Berg balance scale to 6 months
Time Frame: 6 months
|
in the off-medication condition
|
6 months
|
Change from baseline 39-item Parkinsons disease questionnaire to 4 months
Time Frame: 4 months
|
4 months
|
|
Change from baseline 39-item Parkinsons disease questionnaire to 6 months
Time Frame: 6 months
|
6 months
|
|
Change from baseline Levodopa equivalent daily dose to 4 months
Time Frame: 4 months
|
4 months
|
|
Change from baseline Levodopa equivalent daily dose to 6 months
Time Frame: 6 months
|
6 months
|
|
Change from baseline maximal phonatory time to 4 months
Time Frame: 4 months
|
4 months
|
|
Change from baseline maximal phonatory time to 6 months
Time Frame: 6 months
|
6 months
|
|
Change from baseline dysphonia severity index to 4 months
Time Frame: 4 months
|
4 months
|
|
Change from baseline dysphonia severity index to 6 months
Time Frame: 6 months
|
6 months
|
|
Change from baseline Mini-Mental Status Exam to 4 months
Time Frame: 4 months
|
4 months
|
|
Change from baseline Mini-Mental Status Exam to 6 months
Time Frame: 6 months
|
6 months
|
|
Change from baseline Beck depression inventory to 4 months
Time Frame: 4 months
|
4 months
|
|
Change from baseline Beck depression inventory to 6 months
Time Frame: 6 months
|
6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
May 1, 2022
Primary Completion (ANTICIPATED)
May 1, 2025
Study Completion (ANTICIPATED)
May 1, 2027
Study Registration Dates
First Submitted
May 1, 2022
First Submitted That Met QC Criteria
May 16, 2022
First Posted (ACTUAL)
May 19, 2022
Study Record Updates
Last Update Posted (ESTIMATE)
February 14, 2023
Last Update Submitted That Met QC Criteria
February 12, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TDPSA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Deep brain stimulation
-
Abbott Medical DevicesTerminatedDepressive Disorder, Major | Unipolar DepressionUnited States, Canada, United Kingdom
-
Zhiqi MaoRecruitingParkinson's Disease | Executive Function | Electroencephalogram | Functional Near - Infrared SpectroscopyChina
-
Ali Rezai, MDCompleted
-
University Hospital Inselspital, BerneCompletedMovement Disorder | Urinary Tract DiseaseSwitzerland
-
University of MinnesotaRecruitingParkinson DiseaseUnited States
-
NewronikaTerminatedParkinson DiseaseItaly
-
Butler HospitalMedtronicCompletedObsessive-Compulsive DisorderUnited States
-
University of Sao Paulo General HospitalUnknownCerebellar AtaxiaBrazil
-
Boston Scientific CorporationCompletedParkinson's DiseaseUnited States
-
Qilu Hospital of Shandong UniversityRecruiting